Hikal's Q4 financial results show strong growth in key areas.

Hikal, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. The company has shown a positive performance in this quarter, with a significant improvement in its financial score from -9 to 7 in the last three months.

One of the key highlights of Hikal's financials for this quarter is the growth in its Profit Before Tax (PBT) less Other Income, which has increased by 98.6% to Rs 46.86 crore compared to the average PBT of the previous four quarters at Rs 23.60 crore. This indicates a very positive trend in the near term for the company's PBT.

Similarly, the Profit After Tax (PAT) for this quarter has also shown a significant growth of 89.7% to Rs 33.97 crore compared to the average PAT of the previous four quarters at Rs 17.91 crore. This is another positive trend for Hikal in the near term.

In terms of Operating Profit (PBDIT), Hikal has achieved its highest figure in the last five quarters at Rs 94.46 crore. This shows a positive trend in the near term for the company's operating profit.

Moreover, Hikal's Operating Profit Margin for this quarter is also at its highest in the last five quarters at 18.37%. This indicates an improvement in the company's efficiency.

Overall, Hikal's financial results for the quarter ending March 2024 have shown a positive trend, with significant growth in key areas. However, it is important to note that MarketsMOJO has given a 'Sell' call for the company's stock.